Does routine peri-operative continuous cell salvage in cardiac surgery reduce exposure to allogeneic blood? A randomised controlled trial
Completed
- Conditions
- Blood transfusion following cardiac surgerySurgeryCardiac surgery
- Registration Number
- ISRCTN17615029
- Lead Sponsor
- Papworth Hospital NHS Trust (UK)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 206
Inclusion Criteria
Patients for non-emergency first-time Coronary Artery Bypass Grafting (CABG) with planned use of cardiopulmonary bypass, and patients for valve repair or replacement, or combined CABG and valve procedure.
Exclusion Criteria
1. Refusal to receive blood or blood products
2. Previous cardiac or thoracic surgery
3. Having an unacceptable risk, as per investigator judgement
4. Known serious coagulation disorders
5. Known blood disorder (thalassemia, chronic anaemia, lymphoproliferative disorder etc.)
6. Any contra-indication to antifibrinolytics
7. The receipt of any investigational drug or participation in a device trial during the course of this trial
8. Where a specific request for cell salvage has been made by the surgeon
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The proportion of patients exposed to allogeneic blood. All outcomes measured at 30 days post surgery.
- Secondary Outcome Measures
Name Time Method 1. The number of units of allogeneic red blood cells transfused during first-time cardiac surgery<br>2. The use of blood products such as fresh frozen plasma and platelet concentrates<br>3. Adverse events<br>4. Resource use and cost savings of using CATS in this specific group of patients<br><br>All outcomes measured at 30 days post surgery.